The Frequency of Non-Scarring Alopecia in Autoimmune Connective Tissue Diseases

March 2025 | Volume 24 | Issue 3 | 246 | Copyright © March 2025


Published online February 24, 2025

doi:10.36849/JDD.7750

Yahya Argobi MD FAAD

King Khalid University, Abha, Saudi Arabia; Department of Dermatology, Massachusetts General Hospital, Boston, MA

Abstract
Background: Autoimmune connective tissue diseases (ACTDs) are relatively rare systemic diseases featured by immune dysregulation and often have prominent cutaneous manifestations. The most common is systemic lupus erythematosus (SLE), dermatomyositis (DM), systemic sclerosis (SSc), Sjogren syndrome (SJO), undifferentiated connective tissue disease (UCTD), and mixed connective tissue disease (MCTD). Alopecia is one of the most common symptoms of these diseases, with significant impact on the quality of life of these patients.
Objective: Our aim is to better characterize non-scarring alopecia in ACTDs.
Methods: A retrospective chart review study of patients seen at the Autoimmune Connective Tissue Diseases clinic at Massachusetts General Hospital, Boston, MA, was conducted from November 2012 to January 2018. The study was reviewed and approved by Partners IRB.
Results: A total number of 1486 visits where 734 were new patients, and 241 patients with ACTDs included in our analysis. Of the new patients, 80% were female and 20% were male, with an average age of 51 years. Of patients with MCTD, 46.6% presented with non-scarring alopecia at their initial evaluation. Of patients with SLE, 36% presented with non-scarring alopecia. Of the 32 patients with SJO, 28% reported diffuse non-scarring alopecia. Of patients with UCTD, 22% presented with diffuse non-scarring alopecia. Only 9.5% of our patients with DM and 9% of our patients with SSc presented with diffuse non-scarring alopecia.
Conclusion: Alopecia is common in all ACTDs and often under evaluated. Treatment of alopecia in ACTDs can be challenging, and oftentimes patients require joint management and work-up.

J Drugs Dermatol. 2025;24(3):246-249. doi:10.36849/JDD.7750

INTRODUCTION

Alopecia is a common troubling symptom in dermatology. It can be divided into various categories and is usually classified clinically and histopathologically into scarring and non-scarring alopecia.1 It can also be subdivided based on etiology such as genetic, nutritional deficiency, endocrine, infectious, and autoimmune. There is an overlap between these categories, eg, scarring alopecia can be autoimmune, but not all autoimmune alopecias are scarring.1 The human hair follicles are immune-privileged structures, and under normal circumstances, they are protected from immune damage.2 Autoimmune-associated hair loss results whenever there is a collapse in this immune privilege. Autoimmune alopecia refers to hair loss secondary to an underlying autoimmune skin disease. This includes alopecia from lichen planopilaris (LPP), bullous diseases, and connective tissue diseases. In this paper, we focused on autoimmune connective tissue disease (ACTD)-related hair loss, and in particular non-scarring alopecia. ACTDs are a relatively rare group of multisystem diseases characterized by immune dysregulation and autoantibodies. The most common include systemic lupus erythematosus (SLE), dermatomyo¬sitis (DM), systemic sclerosis (SSc), Sjogren syndrome (SJO), undifferentiated connective tissue disease (UCTD), and mixed connective tissue disease (MCTD). They usually present with characteristic signs and symptoms. Cutaneous manifestations and hair loss are common in ACTDs. There are few studies of alopecia in ACTDs, and most of them focus on SLE and discoid lupus erythematosus (DLE). However very little is known about alopecia in other less common ACTDs. We performed this study to better understand the frequency and characteristics of non-scarring alopecia in different ACTDs.

MATERIALS AND METHODS

This study was performed to characterize non-scarring alopecia, timing relative to disease onset of hair loss in different ACTDs, to identify if these characteristics can be related to potentially different etiologies of non-scarring alopecia, and to examine the frequency with which non-scarring alopecia is evaluated and treated in ACTDs in standard vs specialty dermatology-rheumatology clinical care.